Home » Newsletters » BioWorld Science

BioWorld Science

May 16, 2013

View Archived Issues

Mirabegron/solifenacin as an effective therapeutic option for overactive bladder

Imanova presents novel imaging tracer candidates

NIHR collaborates with companies on Alzheimer disease biomarker discovery

One-step generation of transgenic mice with multiple mutations

Vectura establishes strategic partnership in China for new respiratory business

The discovery of an antimicrobial adjuvant for sensitizing multidrug-resistant bacteria

Takeda Pharmaceutical presents highlights of fiscal 2012

New phase III study evaluates Stivarga in advanced hepatocellular carcinoma

Two new trials under way in sarilumab phase III program

OncoMed's anti-Notch 2/3 antibody OMP-59R5 begins study in SCLC

Herbal cream safely and effectively relieves symptoms of psoriasis

NP-260 shows efficacy in animal models of neuropathic pain

Soligenix begins phase I study of SGX-203 in pediatric Crohn's disease

Ultragenyx to conduct phase I/II trial of UX-003 for MPS VII

Elixir Medical receives CE mark approval for the DESolve Scaffold System

Ono Pharmaceutical updates developments of fourth quarter 2012

TaiGen seeks approval for oral formulation of nemonoxacin in Taiwan and China

Sanofi discloses novel PKC-beta inhibitors

Merck & Co. patents novel OX2 receptor antagonists

Chinese group presents new DGAT1 inhibitors

Researchers at Torrent Pharmaceuticals synthesize new TGR5 agonists

NewVac patents novel A2A receptor antagonists

Janssen obtains FDA approval for use of Simponi in new indication

FDA approves Xofigo in treatment of CRPC with bone metastases

XBiotech reports results on use of Xilonix in treatment-refractory NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...